We are now proposing AMBRA1 as a novel target to reduce oxidative stress; indeed, this molecule could be modulated in the future as a pharmacological target in brains of PD patients or other patients with pathologies associated to oxidative stress. This evidence concerns the gene AMBRA1 and Parkinson disease.